drugset / Trial / NCT04920032
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Phase 1
Recruiting
22 enrolled
University of California, Irvine
Natera, Inc. · collabTaiho Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
Timeline
- Start
- 2021-08-26
- Primary completion
- 2027-01-21
- Completion
- 2028-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | TAS-102 | Small molecule | 25 mg/m2 | Oral |